LONDON, April 8, 2014 /PRNewswire/ --
On Monday, April 07, 2014, the
NASDAQ Composite ended at 4,079.75, down 1.16%, the Dow Jones
Industrial Average finished the session 1.02% lower at 16,245.87,
and the S&P 500 closed at 1,845.04, down 1.08%. The losses were
broad based as nine out of ten sectors finished on a lower note.
The S&P 500 Health Care Sector Index finished the day 1.06%
lower at 664.68, while the same has gained 3.19% in the previous
three months. Investor-Edge has initiated coverage on the following
equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Celgene Corp.
(NASDAQ: CELG), PDL BioPharma Inc. (NASDAQ: PDLI) and Hemispherx
Biopharma Inc. (NYSE MKT: HEB). Free technical research on ARNA,
CELG, PDLI and HEB can be downloaded upon signing up at:
http://www.investor-edge.com/905-register
On Monday, shares in Arena Pharmaceuticals Inc. gained 2.57% to
close the day at $6.38. The stock
recorded a trading volume of 5.82 million shares, as compared with
its three months average volume of 6.14 million shares. The stock
oscillated between $6.08 and $6.42
during the trading session. Arena Pharmaceuticals Inc.'s shares
have fallen by 4.35% in the previous three trading sessions and
10.39% in the last one month, while the same has gained 9.06% on
YTD basis. The stock is trading below its 50-day moving average.
Arena Pharmaceuticals Inc.'s 50-day moving average of $6.61 is above its 200-day moving average of
$6.25. Moreover, the stock has a
Relative Strength Index (RSI) of 43.96. Sign up today to read free
research on ARNA at:
http://www.investor-edge.com/905-ARNA-08Apr2014.pdf
Celgene Corp.'s stock finished the session 1.30% higher at
$139.16. A total of 6.77 million
shares were traded, which is above their three months average
volume of 3.75 million shares. The stock fluctuated between
$135.50 and $140.68 during the
session. The company's shares traded at a PE ratio of 29.73.
Celgene Corp.'s stock has declined 5.60% in the previous three
trading sessions, 11.11% in the last one month and 17.64% on YTD
basis. The stock is trading below its 50-day and 200-day moving
averages of $154.44 and $150.71, respectively. Additionally, the stock
has an RSI of 33.97. Sign up today to read free research on CELG
at:
http://www.investor-edge.com/905-CELG-08Apr2014.pdf
On Monday, PDL BioPharma Inc.'s stock recorded a trading volume of
4.08 million shares, as compared with its three months average
volume of 3.19 million shares. The stock ended the day at
$8.20, up 1.74%, after vacillating
between $7.98 and $8.24. Shares of the company traded at a PE ratio
of 4.74. PDL BioPharma Inc.'s shares have lost 0.97% in the
previous three trading sessions, 0.85% in the last one month and
2.84% on YTD basis. The company's stock is trading below its 50-day
and 200-day moving averages of $8.47
and $8.31, respectively. Furthermore,
shares of the company have an RSI of 42.16. Sign up today to read
free research on PDLI at:
http://www.investor-edge.com/905-PDLI-08Apr2014.pdf
Shares in Hemispherx Biopharma Inc. reported a trading volume of
0.71 million shares, as compared with its three months average
volume of 3.36 million shares. The stock ended the day 6.13% lower
at $0.38, and at an intraday range of
$0.37 and $0.39. Hemispherx Biopharma Inc.'s shares have
fallen by 7.05% in the previous three trading sessions and 5.22% in
the last month, while the stock has gained 41.70% on YTD basis. The
stock is trading below its 50-day moving average. Hemispherx
Biopharma Inc.'s 50-day moving average of $0.41 is above its 200-day moving average of
$0.29. Further, the stock has an RSI
of 48.86. Sign up today to read free research on HEB at:
http://www.investor-edge.com/905-HEB-08Apr2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
3. This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at
compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage
on your company? Send us a full investors' package to research [at]
http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis.
This document, article or report is prepared and authored by
Investor-edge. An outsourced research services provider represented
by Nidhi Vatsal, CFA, has only reviewed the information provided by
Investor-edge in this article or report according to the Procedures
outlined by Investor-edge. Investor-edge is not entitled to veto or
interfere in the application of such procedures by the outsourced
provider to the articles, documents or reports, as the case may
be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or
otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Investor-edge
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Investor-edge expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Investor-edge does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the
information. The included information is subject to change without
notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Investor-Edge